Clinical and mycologic characteristics of onychomycosis in diabetic patients

Acta Dermatovenerologica Croatica

Volumn 18, Issue 2, 2010, Pages 84-91

  Al Mutairi, Nawaf ^a   Eassa, Bayoumy Ibrahim ^a   Al Rqobah, Dhuha Abdullah ^a  

^a FARWANIYA HOSPITAL   (Kuwait)

Author keywords

Diabetes; Onychomycosis; Risk factors

Indexed keywords

POTASSIUM HYDROXIDE; TERBINAFINE;

ADULT; AGED; AGING; ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; DERMATOPHYTE; DIABETES MELLITUS; DIABETIC PATIENT; FEMALE; FINGERNAIL ONYCHOMYCOSIS; FUNGUS CULTURE; FUNGUS ISOLATION; HIGH RISK PATIENT; HUMAN; MAJOR CLINICAL STUDY; MALE; RELAPSE; TOENAIL ONYCHOMYCOSIS; TREATMENT DURATION; TREATMENT RESPONSE;

ADOLESCENT; ADULT; AGED; CASE-CONTROL STUDIES; COHORT STUDIES; DIABETES COMPLICATIONS; FEMALE; FOOT DERMATOSES; HUMANS; MALE; MIDDLE AGED; ONYCHOMYCOSIS; PREVALENCE; YOUNG ADULT;

EID: 77956239931     PISSN: 1330027X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (34)

1. Al-Mutairi N, Zaki A, Sharma AK, Al-Sheltawi M. Cutaneous manifestations of diabetes mellitus. Med Princ Pract 2006;15:427-430.
2. Williams HC. The epidemiology of onychomycosis in Britain. Br J Dermatol 1993;129:101-109.
3. Faergemann J, Baran R. Epidemiology, clinical presentation and diagnosis of onychomycosis. Br J Dermatol 2003;149:1-4.
4. Summerbell RC, Kane J, Krajden S. Onychomycosis, tinea pedis and tinea manuum caused by non-dermatophytic filamentous fungi. Mycoses 1989;32:609-619.
5. Gupta AK, Konnikov N, MacDonald P, Rich P, Rodger NW, Edmonds MW, et al. Prevalence and epidemiology of toenail onychomycosis in diabetic subjects: a multicentre survey. Br J Dermatol 1998;139:665-671.
6. Rich P. Special patient populations: onychomycosis in the diabetic patient. J Am Acad Dermatol 1996; 35: S10-S2.
7. Gupta AK, Humke S. The prevalence and management of onychomycosis in diabetic patients. Eur J Dermatol 2000;10:379-384.
8. Hay RJ. The Achilles Project: How common are fungal foot infections in Europe? Proceedings of the Satellite Symposium, Eighth Congress of the European Academy of Dermatology and Venereology (EADV), 1999.
9. th Annual International Meeting of the International Society for Pharmaco-economics and Outcomes Research (ISPOR), May 23-26, 1999, Arlington, VA, USA.
10. Dogra S, Kumar B, Bhansali A, Chakrabarty A. Epidemiology of onychomycosis in patients with diabetes mellitus in India. Int J Dermatol 2002;41:647-651.
11. Skorepova M. Mycoses and diabetes. Vnitr Lek 2006;52:470-473.
12. Piérard GE, Piérard-Franchimont C. The nail under fungal siege in patients with type II diabetes mellitus. Mycoses 2005;48:339-342.
13. Aida LS, Sanchez JL, Puerto SJ. Prevalence of dermatophytosis in patients with diabetes. J Am Acad Dermatol 1992;26:408-410.
14. Buxton PK, Milne LJ, Precocott W, Proudfoot MC, Stuart FM. The prevalence of dermatophyte infection in well controlled diabetics and the response to Trichophyton antigen. Br J Dermatol 1996;134:900-903.
15. Alteras I, Saryt E. Prevalence of pathogenic fungi in toe webs and toe nails of diabetic patients. Mycopathologica 1979;67:157-159.
16. Romano C, Massai L, Asta F, Signorini AM. Prevalence of dermatophytic skin and nail infections in diabetic patients. Mycoses 2001;44:83-86.
17. Robert DT. Prevalence of dermatophyte onychomycosis in the United Kingdom: result of a survey. Br J Dermatol 1991;126:23-27.
18. Saunte DM, Holgersen JB, Haedersdal M, Strauss G, Bitsch M, Svendsen OL, et al. Prevalence of toe nail onychomycosis in diabetic patients. Acta Derm Venereol 2006;86:425-428.
19. Drake LA, Dinehart SM, Farmer ER, Goltz RW, Graham GF, Hordinsky MK, et al. Guidelines of care for superficial mycotic infections of the skin: onychomycosis. J Am Acad Dermatol 1996;34:116-121.
20. Elewski BE, Charif MA. Prevalence of onycho-mycosis: highlights of the Third Annual International Summit on Cutaneous Antifungal Therapy. Clin Infect Dis 1997;23:305-313.
21. Tasic S, Stojanovic S, Polijacki M. Etiopathogenesis, clinical picture and diagnosis of ony-chomycosis. Med Pregl 2001;54:45-51.
22. Al-Sogair SM, Moawad MK, Al-Humadan YM. Fungal infection as a cause of skin disease in the eastern province of Saudi Arabia: prevailing fungi and pattern of infection. Mycoses 1991;34:333-337.
23. th ed. New York, NY: McGraw-Hill, 2003:1989-2005.
24. English MP. Nails and fungi. Br J Dermatol 1976;94:697-701.
25. Andre J, Achten G. Onychomycosis. Int J Dermatol 1987;26:481-490.
26. Haneke E. Fungal infections of the nail. Semin Dermatol 1991;10: 41-53.
27. Lim JT, Chua HC, Goh CL. Dermatophyte and non-dermatophyte onychomycosis in Singapore. Australas J Dermatol 1992;33:159-163.
28. James ST, Warren SJ. Common fungal infections of the feet in patients with diabetes mellitus. Drugs Aging 2004;21:101-112.
29. Roberts DT, Taylor WD, Boyle J. Guidelines for treatment of onychomycosis. Br J Dermatol 2003;148:402-410.
30. Ryder NS, Leitner I. In vitro activity of terbinafine; an update. J Dermatol Treat 1998;9 (Suppl 1):S23-S28.
31. Gupta AK, Ryder JE, Baran R. The use of topical therapies to treat onychomycosis. Dermatol Clin 2003;21:481-489.
32. Farkas B, Paul C, Dobozy A, Hunyadi J, Hor-vath A, Fekete G. Terbinafine (Lamisil) treatment of toenail onychomycosis in patients with insulin-dependent and non-insulin-dependent diabetes mellitus: a multicentre trial. Br J Dermatol 2002;146:254-260.
33. Gupta AK, Gover MD, Lynde CW. Pulse itraconazole vs. continuous terbinafine for the treatment of dermatophyte toenail onychomycosis in patients with diabetes mellitus. J Eur Acad Dermatol Venereol 2006;20:1188-1193.
34. Bohannon NJ, Streja L. Effectiveness of terbinafine therapy for toenail onychomycosis in persons with diabetes. Diabetes 2000;49(Suppl 1):A195.